SBIR/STTR Research Award

Topoisomerase Targeting Agents Predicated on Polyamine Architectures

Award identifier b964e0024def67964899580f4f53defa0192a0e3e1897eaafa7fa831bc403292Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$153,630

Program and phase

SBIR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Topogen, Inc
Proposal award date
Not reported
Contract end date
Not reported
UEI
NBL9ZBTWHV15
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Drugs that target topoisomerase action are effective anticancer agents and a number are FDA approved. Anti-topoisomerase therapy is predicated on subverting the endogenous topoisomerase into a genotoxic, DNA damaging ag ent. A significant problem with such drugs is collateral damage in normal cells. Since all nucleated somatic cells retain some level topoisomerase activity (either type I and/or type II), negative outcome due to DNA damage in normal healthy tissue is unavo idable, unless novel strategies can be crafted to tune down undesirable side effects. In this SBIR, the corporate sponsor (TopoGEN, Inc.) is proposing a combinatorial strategy using smart pharma' drug design. Potent topoisomerase poisons can be coupled to polyamines (spermine for example) which are processed preferentially by cancer cells based on elevated requirement of exogenous polyamines for cell growth. Evidence is provided that novel anti- topoisomerase/polyamine conjugates induce preferential DNA da mage via endogenous topoisomerase poisoning in cells with hyperactive polyamine transport mechanisms. A library of novel polyamine compounds of this sort has been synthesized (and others are being constantly added). In this SBIR, the company will rigorousl y evaluate these novel compounds for topoisomerase targeting efficacy in vivo using defined model cells lines and in vitro using purified enzymes. This strategy for rational polyamine-topoisomerase drug design will reveal the most effective agents for canc er cell killing while minimizing damage to normal cells. PUBLIC HEALTH RELEVANCE: The development of targeted cancer therapies would be a clear advance in the treatment of cancer. Since cancer costs in the U.S. were nearly 1.4 million lives and 210 billio n in 2005, it makes both medical and economic sense to invest in new pharmaceutical technologies. Smart drugs, which can selectively target and kill cancers, would begin to address this important public health issue.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

8 SBIR/STTR records share this UEI (1997–2020). Reported award amounts total $2,647,740. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.